Markets
LLY

Lilly To Buy Disarm Therapeutics For Upfront Payment Of $135.0 Mln

(RTTNews) - Eli Lilly and Co. (LLY) said that it agreed to buy a privately-held biotechnology company Disarm Therapeutics for an upfront payment of $135.0 million.

As per the deal, Disarm equityholders may be eligible for up to $1.225 billion in additional future payments for potential development, regulatory and commercial milestones should Lilly successfully develop and commercialize new medicines resulting from the acquisition.

There will be no change to Lilly's 2020 non-GAAP earnings per share guidance as a result of the deal, Eli Lilly said in a statement.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LLY

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More